Seeking Alpha

Introducing The Global X Cannabis ETF

|
Includes: POTX
by: Global X ETFs
Summary

On September 19th, 2019, the Global X Cannabis ETF began trading on Nasdaq.

POTX seeks to invest in companies across the cannabis industry.

A trifecta of forces - regulatory overhaul, changes in public opinion, and a large, proven addressable market - makes cannabis an attractive theme in its very early stages.

Despite the potential risks, we see vast opportunities in gaining broad exposure to the cannabis space as the nascent industry rapidly emerges.

On September 19th, 2019, the Global X Cannabis ETF (NASDAQ:POTX) began trading on Nasdaq. POTX seeks to invest in companies across the cannabis industry. This includes companies involved in the legal production, growth and distribution of cannabis and industrial hemp, as well as those involved in providing financial services to the cannabis industry, pharmaceutical applications of cannabis, cannabidiol (i.e., CBD), or other related uses including but not limited to extracts, derivatives or synthetic versions.

In recent years, public opinion and the global regulatory environment have generally shifted towards a more supportive stance on legalization efforts surrounding the growing and selling of cannabis and related products. As these efforts show signs of continuing across the US and around the world, additional regulated markets could enter the fray, bringing billions of dollars of potential revenue with them. In 2019 alone, global sales of legal cannabis are expected to reach $14.9 billion, rising 36% year-over-year, but still representing less than 9% of the total market.1,2 Given this momentous shift and the large potential market, companies operating lawfully across various aspects of the cannabis value chain possess high growth potential in this budding market.

In this piece, we discuss the state of the cannabis industry, including drawing parallels to the end of the alcohol prohibition era, analyzing how the market has changed in places like Colorado and Canada since legalization, additional potential markets for legalization, and the use cases for cannabis in medicinal and industrial capacities.

Cannabis Legalization Parallels Alcohol Prohibition Repeal

There are few instances where regulations shift so quickly and dramatically that multi-billion-dollar industries are formed virtually overnight. Yet one can look to the repeal of alcohol prohibition in the United States as an early precursor to the cannabis legalization efforts currently underway.

From 1920 to 1933, producing, importing, transporting, and selling alcoholic beverages was banned in the United States, costing the federal government an estimated of $11 billion in lost tax revenue and eliminating thousands of jobs.3 The subsequent repeal of alcohol prohibition in late 1933 quickly brought back buoyant economic activity. For the federal government, it meant $1.35 billion in alcohol-related taxes, representing half of the federal government's total revenue in 1934.4 For the economy as a whole, the annual net social benefits were estimated to be $3.5 billion in today's prices, or one-third of 1% of GDP in the 1934-1937 period.5 And after the repeal, thousands of workers found jobs in the industry again.6 The job multiplier effect allowed for creation of jobs in agriculture, retail-end of liquor industry (e.g. bars, restaurants), dispensaries and clerical-related jobs.

While just a handful of breweries and distilleries survived the prohibition era by switching their production to non-alcohol related products, these companies were ready to capitalize on the prohibition repeal and resume their position in the revamped industry. They possessed the specific machinery and expertise to quickly ramp up alcohol production and capture the growing market. The beer industry became regionally monopolized, as large companies took over small scale producers.7 Production of spirits was even more concentrated in the years following the repeal, with roughly four-firths of all distilled liquor made in the US being produced by four corporations.8

Post-prohibition, data on per capita consumption of alcohol suggests that alcohol use in the US increased after 1933, as the act was no longer illicit and social norms evolved.9

As cannabis becomes legalized in additional countries and states, we believe the post-prohibition era is an apt comparison for the potential growth of the industry. Searching for ways to boost economic growth and tax receipts, many governments are likely to consider taking a positive stance on legalization. Large established players with expertise and capital, are likely to take a commanding position in the global market, quickly entering new markets as they open and consolidating market share. And as regulations change, we expect consumer habits to evolve too, with stigmas associated with cannabis usage removed in recreational, medicinal, and health and wellness capacities.

The Impact of Legalization in Colorado

Since allowing recreational retail distribution of cannabis in 2014, Colorado's monthly sales figures offer more recent insights into the potential growth trajectory of newly legalized markets. Recreational sales started at $14 million per month in 2014, growing to over $122 million by June 2019, representing a 48% compound annual growth rate (CAGR).10 In June 2019, Colorado reached combined monthly recreational and medical sales of $152 million, or a $1.8 billion annual revenue run rate.11 Total sales since legalization stand at roughly $6.8 billion.12

Colorado's cannabis industry has generated meaningful economic growth and tax revenues. A Kansas City Fed study on the economic impact of cannabis legalization found that Colorado created roughly 18,000 direct jobs, boosted another 23% by spurring indirect employment from areas like construction, security, and legal services.13 Further, taxes on cannabis sales, which includes a 15% excise tax, 15% special sales tax, and a 2.9% state sales tax, have raised over $1 billion for the state since legalization, providing funding for school construction, local governments, and cannabis research.14

Beyond the economic success of legalization in Colorado, social attitudes towards cannabis consumption have continued their multi-decade shift. Last year, 62% of Americans supported full recreational cannabis legalization, up from just 12% in 1969, and up from 54% in 2014 when Colorado first approved recreational use.15

The meaningful economic benefits, along with rising social acceptance, have played a major role in swaying policymakers from other states to support legalizing cannabis sales. While cannabis is still classified as Schedule I drug by the US Drug Enforcement Agency and subject to The Controlled Substances Act (CSA) at the federal level, 33 states have approved medical use and 11 states have approved both medical and recreational use. Other states like Ohio, Arizona, and Florida are considering introducing recreational cannabis legalization on upcoming ballots.

What's been the (short, but promising) experience in Canada?

In October 2018, Canada achieved a milestone as the first G-7 country to fully legalize adult use of recreational cannabis. Since then, cannabis consumption has been on the rise, with 17.5% of Canadians reporting use, up from 14% a year ago, prior to legalization.16 In addition, sales of various medical and non-medical forms of cannabis increased 53% in the aggregate less than a year since recreational use was first allowed.

Post-legalization, Canada has emerged as the epicenter for the global cannabis industry. With a supportive regulatory environment nationwide, Canadian companies are uniquely able to build inventories and develop differentiated brands and products; an advantage that has catapulted many Canadian firms to become leaders in the space. Such efforts are part of many Canadian License Producers (LPs) plans to supply and serve international markets once regulations allow for the use of recreational cannabis, including in the US.

Currently, Canadian LPs may only enter the US by selling hemp or CBD products, which were legalized for cultivation and sale on December 12th with the 2018 Farm Bill. LPs have also acquired rights to control US companies once cannabis is legalized at a federal level. For example, Canopy Growth (OTC:CGC), which operates in the recreational cannabis market in Canada and in other legal medical markets around the world, announced on April 19th that it reserves the right to acquire the US based company, Acreage Holdings (OTCQX:ACRGF) (OTC:ACRZF), for $3.4 billion, once cannabis is legalized at a federal level in the US.

Additional Potential Markets

We believe that today's leading companies in the cannabis space are well-positioned to capitalize on the expected future growth of cannabis in pharmaceutical, health & wellness, and recreational products. As discussed earlier in this piece, the legal cannabis industry remains in its infancy, with an expected $14.9 billion in sales in 2019 relative to an estimated $166 billion total addressable market (TAM).17 As legalization efforts take place around the world, this should continue to grow the pie significantly for firms engaged in the legal sale of cannabis and related products. Mexico and New Zealand could be the next countries to legalize recreational cannabis; the former looking to propose the legislation in 2019 in order to reduce cartel activity in the country, and the latter with legalization plans by 2020, launching a referendum on legalization alongside general elections.

Beyond Recreational Use

Cannabis has many other uses outside the recreational space that represent further potential growth for the space. In the industrial space, hemp and its derivatives are increasingly used in building materials, plastics, textiles, paper, and fuel. In the medicinal space, research is still in its early stages of understanding cannabis, driving many pharmaceutical firms to begin clinical trials evaluating cannabinoid therapies for various diseases. With only one cannabis-derived drug being approved by the US Food and Drug Administration (FDA), the market remains a nascent one. GW Pharmaceuticals (NASDAQ:GWPH) (OTCPK:GWPRF) is behind the development of this drug, Epidiolex, which treats seizures associated with Lennox-Gastaut syndrome and Dravet Syndrome, two rare and severe childhood-onset, drug-resistant epilepsy syndromes.18 GW Pharmaceuticals is testing other drugs based on cannabinoids, but it is not the only company behind the opportunities in the medical cannabis space as can be seen in the table below. The breadth of indications encompasses neurological, psychiatric, immune, pain, gastrointestinal and other areas.

Conclusion

A trifecta of forces - regulatory overhaul, changes in public opinion, and a large, proven addressable market - makes cannabis an attractive theme in its very early stages. Early investors in the space can expect to experience high volatility as the theme takes hold, with new companies formed and developed, and public policy following a bumpy, unpredictable path, even if long term trends point to greater liberalization of cannabis regulation. Despite the potential risks, we see vast opportunities in gaining broad exposure to the cannabis space as the nascent industry rapidly emerges.

Related ETFs

POTX: The Global X Cannabis ETF seeks to invest in companies across the cannabis industry value chain, including companies involved in the legal production, growth and distribution of cannabis and industrial hemp, as well as those involved in providing financial services to the cannabis industry, pharmaceutical applications of cannabis, cannabidiol (i.e., CBD), or other related uses including but not limited to extracts, derivatives or synthetic versions.

Footnotes

1. BDS Analytics, "New Report: Global Legal Cannabis Markets to Grow 36% in 2019 Despite 2018 Challenges; To Break $40 Billion by 2024," Jun 20, 2019.

2. BofA Merrill Lynch, "A cannabis world…and more people are living in it," Apr 17, 2019.

3. PBS, "Prohibition: Unintended Consequences."

4. History, "How the Misery of the Great Depression Helped Vanquish Prohibition," Feb 22, 2019.

5. Contemporary Economic Policy, "Repeal of Prohibition: A Benefit-Cost Analysis," Apr 7, 2014.

6. New York Times, "50,000 barrels ready in St Louis," Mar 23, 1933.

7. Milbank Memorial Fund, "From Prohibition to Regulation: Lessons from Alcohol Policy for Drug Policy," 1991.

8. Ibid.

9. Society for the Study of Addiction, "What are the policy lessons of National Alcohol Prohibition in the United States, 1920-1933?," Jun 8, 2010.

10. Colorado Department of Revenue, "Marijuana Sales Report," Aug 2019.

11. Ibid.

12. Ibid.

13. Kansas City Fed, "The Economic Effects of the Marijuana Industry in Colorado," Apr 16, 2018.

14. Colorado Department of Revenue, "Marijuana Tax Data," Updated Aug 2019.

15. Pew Research, "About six-in-ten Americans support marijuana legalization," Oct 8, 2018.

16. Statistics Canada, "Analysis of trends in the prevalence of cannabis use and related metrics in Canada," Jun 19, 2019.

17. BofA Merrill Lynch (n2).

18. GW Pharmaceuticals website, About Us.

Investing involves risk, including the possible loss of principal. The investable universe of companies in which POTX may invest may be limited. The Fund invests in securities of companies engaged in Healthcare and Pharmaceutical sectors. These sectors can be affected by government regulations, expiring patents, rapid product obsolescence, and intense industry competition. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. POTX is non-diversified.

Cannabis Companies are subject to various laws and regulations that may differ at the state/local, federal and international level. These laws and regulations may significantly affect a Cannabis Company’s ability to secure financing and traditional banking services, impact the market for cannabis business sales and services, and set limitations on cannabis use, production, transportation, export and storage. The Fund’s investments are concentrated in the cannabis industry, and the Fund may be susceptible to loss due to adverse occurrences affecting this industry.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. The closing price is the Mid-Point between the Bid and Ask price as of the close of exchange. Closing price returns do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses which may be obtained by calling 1-888-GX-FUND-1 (1.888.493.8631), or by visiting globalxetfs.com. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.